Your browser doesn't support javascript.
loading
Risk of post-sphincterotomy bleeding with antiplatelet and anticoagulant use: a propensity-matched analysis of the U.S. Collaborative Network.
Chandan, Saurabh; Desai, Aakash; Dahiya, Dushyant S; Ramai, Daryl; Mohan, Babu P; Facciorusso, Antonio; Adler, Douglas G; Kochhar, Gursimran S.
Afiliação
  • Chandan S; Division of Gastroenterology and Hepatology, Creighton University School of Medicine, Omaha, Nebraska, USA. Electronic address: saurabhchandan@gmail.com.
  • Desai A; Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Dahiya DS; Department of Internal Medicine, Central Michigan University College of Medicine, Saginaw, Michigan, USA.
  • Ramai D; Department of Gastroenterology, University of Utah, Salt Lake City, Utah, USA.
  • Mohan BP; Department of Gastroenterology, University of Utah, Salt Lake City, Utah, USA.
  • Facciorusso A; Gastroenterology Unit, Department of Surgical and Medical Sciences, University of Foggia, Foggia, Italy.
  • Adler DG; Center for Advanced Therapeutic Endoscopy (CATE), Centura Health, Porter Adventist Hospital, Denver, Colorado, USA.
  • Kochhar GS; Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
Gastrointest Endosc ; 97(6): 1129-1136.e3, 2023 06.
Article em En | MEDLINE | ID: mdl-36731579
BACKGROUND AND AIMS: GI bleeding after ERCP is a serious adverse event and most commonly occurs after endoscopic biliary and/or pancreatic sphincterotomy. Although the strength of available evidence for post-sphincterotomy GI bleeding risk is high for therapeutic warfarin and heparin, it remains unknown for antiplatelet agents like clopidogrel and prasugrel. We conducted a retrospective United States-based, propensity-matched cohort study to assess the risk of post-sphincterotomy bleeding in patients receiving anticoagulant (AC) and antiplatelet (APT) therapy. METHODS: We analyzed the U.S. Collaborative Network in the TriNetX platform through December 27, 2022, to include patients receiving APT and AC therapy who underwent ERCP within 7 days of hospitalization. One-to-one propensity score matching was performed. The primary outcome was the incidence of GI bleeding within 7 days of sphincterotomy. Secondary outcomes included need for blood transfusion, intensive care unit care, and all-cause mortality within 30 days of bleeding. RESULTS: Overall, 2806 patients (1806 in the AC cohort and 1000 in the APT cohort) underwent ERCP with sphincterotomy. One-to-one propensity score matching was performed for age, body mass index ≥30 kg/m2, gender, race, ethnicity, diabetes mellitus, nicotine dependence, presence and severity of chronic kidney disease, cirrhosis, and thrombocytopenia between the cohorts. Patients in both cohorts had an increased risk of post-sphincterotomy bleeding compared with matched control subjects (adjusted odds ratios of 3.6 [95% confidence interval, 2.58-5.06] and 2.2 [95% confidence interval, 1.43-3.56], respectively). Although heparin bridging therapy and concurrent use of aspirin did not further increase the risk of GI bleeding, resumption of AC within 24 hours' postprocedure did. Neither cohort of patients was at an increased risk for blood transfusion, intensive care unit care, or all-cause mortality. CONCLUSIONS: Our database analysis shows that patients receiving AC and APT therapy are at a higher risk of post-sphincterotomy bleeding compared with matched control subjects. An appropriate drug cessation period or alternative biliary decompression modalities may be used in these patients.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esfincterotomia / Anticoagulantes Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esfincterotomia / Anticoagulantes Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article